MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent musi wyrazić świadomą zgodę i być zdolny do udziału w badaniu
- •Nawrotowy glejak wielopostaciowy (GBM) lub astrocytom złośliwy
- •Wiek co najmniej 18 lat
- •Potwierdzony nawrót nowotworu na zdjęciu MRI wykonanym w ciągu 24 dni przed rejestracją
- •Nowotwór o rozmiarze od 1 do 5 cm średnicy
- •Dobry ogólny stan zdrowia (wynik Karnofsky'ego co najmniej 70%)
- •Zdolność do przeprowadzenia zabiegu naczyniowego zgodnie z badaniami ultrasonograficznymi
- •Nowotwór powinien być możliwy do chirurgicznego usunięcia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
M D Anderson Cancer Center
Houston, United States
Trial contact
Frederick Lang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.